EW — Edwards Lifesciences Income Statement
0.000.00%
Last trade - 00:00
- $41.28bn
- $39.95bn
- $6.00bn
- 94
- 21
- 40
- 50
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 4,348 | 4,386 | 5,233 | 5,382 | 6,005 |
Cost of Revenue | |||||
Gross Profit | 3,234 | 3,306 | 3,984 | 4,302 | 4,625 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 3,201 | 3,489 | 3,542 | 3,630 | 4,471 |
Operating Profit | 1,147 | 898 | 1,690 | 1,752 | 1,534 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 1,167 | 917 | 1,702 | 1,767 | 1,598 |
Provision for Income Taxes | |||||
Net Income After Taxes | 1,050 | 823 | 1,503 | 1,522 | 1,399 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 1,047 | 823 | 1,503 | 1,522 | 1,402 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 1,047 | 823 | 1,503 | 1,522 | 1,402 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.79 | 1.88 | 2.41 | 2.54 | 2.62 |